Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.44 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.42 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.42 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.42 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21612772 | 0.92 | PDE4B (0.44) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL23355348 | 0.90 | PDE4B (0.43) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL30203345 | 0.90 | PDE4B (0.43) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL23355345 | 0.88 | MAPT (0.44) | ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL21612843 | 0.87 | PDE4B (0.45) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL21612831 | 0.86 | GPR119 (0.52) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL21612813 | 0.85 | PDE4D (0.49) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL28983495 | 0.85 | GPR119 (0.49) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL30590958 | 0.83 | PDE4B (0.44) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL29205709 | 0.82 | GPR119 (0.52) | PDE4DPDE4BPDE4APDE4CGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-3822263-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-05-19 | — | — | EP | disclosed |
| CN-112334460-A | Biaryl ether type quinazoline derivative | 第一三共株式会社 | 2021-02-05 | — | — | CN | disclosed |
| WO-2020009156-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE | 第一三共株式会社 | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | PDE4D 3905/4885PDE4B 3483/4885PDE4A 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.